Telomir Pharmaceuticals Inc. Common Stock (TELO)

FairStock Score: 40/100 — MIXED

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

As a Buffett and Graham style investor, I look for understandable businesses with durable earnings and a margin of safety. Telomir is a preclinical biotech: no revenue, no approved product, and net losses in every recent period I can see. The filed figures show net losses of $13.1M in FY2023, $16.5M in FY2024, and $10.4M in FY2025. In fiscal Q2 2026, the quarter ended 2026-06-30, it lost $1.7M, or $0.79 per diluted share. Trailing free cash flow is negative $4.9M, a negative 6.6% FCF yield on the $75M market cap at the 2026-10-13 close of $1.09. There is little debt, with D/E of 0.03, and the FairStock-calculated Altman Z-Score is 125.02, but that solvency measure is less comforting for a pre-revenue cash burner. The Piotroski F-Score is 1/9, and the FairStock Score is 40/100. Price-to-book is 7.79, so the market is paying a premium to reported book value for a business with negative ROE of 213.10% and negative ROCE of 122.81%. The Lynch category is none, because losses in each of the last four years fit no category. The investment case rests entirely on Telomir-1 and future clinical or regulatory success, not on present cash flows. That is speculation, not a Graham margin of safety. The stock sits near the low end of its 52-week range, $0.89 to $1.75, but a low price is not the same as cheap when the earnings base is negative. I would need evidence of cash runway, trial progress, and a path to revenue before calling this a sound value proposition.

In plain English: Telomir Pharmaceuticals is a very early-stage drug company with no products on the market and no revenue. It has lost money for years and spends cash on research, so the underlying business looks weak today. At $1.09 a share, the price is near the low end of its last-year range, but with no sales or profits it is not possible to call it cheap or expensive based on normal business results.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer